Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEPCOME-MB: SRS + Binimetinib Encorafenib Pembrolizumab in BRAFV600 Melanoma With Brain Metastasis
NCT04074096Phase 2Active, not recruiting
- Sponsor
- Unicancer
- Start
- Sep 2022
- Primary completion
- May 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of binimetinib, encorafenib, pembrolizumab in melanoma, sponsored by Unicancer. Started Sep 2022; status: active, not recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04074096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04074096.